22/06/2008

Quick diagnoses of drug-resistant TB crucial: experts

Countries with huge caseloads of tuberculosis are finding it hard to cope because they do not have the laboratories to make speedy diagnoses that are essential to save lives.

By Tan Ee Lyn

KUALA LUMPUR (Reuters) - Countries with huge caseloads of tuberculosis are finding it hard to cope because they do not have the laboratories to make speedy diagnoses that are essential to save lives.

Speaking at an infectious disease conference in Kuala Lumpur, TB specialists spoke about how it could take up to five months for patients to get test results and often the patients would be dead by then.

This was especially true for patients with drug-resistant forms of TB and immune systems that were seriously compromised by other diseases, such as AIDS.

Drug-resistant TB is more difficult to treat and patients can die without stronger, second-line drugs.

"We have treatments that are moderately effective and that are available at affordable prices, but the bottleneck is diagnosing the cases and getting them the right treatment," said David Moore, an infectious disease expert at Peru's Cayetano University.

Not only has Peru a substantial caseload of TB. In some parts of the country, up to 6 percent of TB cases are drug-resistant forms. These need to be tested in more sophisticated laboratories, which are in short supply.

"Very few countries in the world have labs to test for resistance and there aren't resources to get samples into labs and results out of labs (in Peru)," Moore said, adding that samples spent most of the time sitting in refrigerators waiting to get transported here and there.

Such delays can be fatal.

"Delayed diagnoses mean they (patients) transmit more to other people and 60 percent of your patients are dead by the time the MDR-TB (multi-drug-resistant TB) results are back," he said.

TREATING THE WRONG TYPE

Roxana Rustomjee, director of the Medical Research Council's TB Unit in Durban, South Africa, said faster diagnoses were urgently needed in Africa, where the most severe form of TB, extensively drug-resistant TB (XDR-TB), is increasingly seen.

Up to 99 percent of patients with XDR-TB die even before they get test results, she told the conference.

"They die of TB because you are treating the wrong (less severe) type of TB," she explained.

In places with advance healthcare systems, such as Hong Kong, it takes 2 weeks to diagnose drug-resistant TB.

Globally, there were 489,139 cases of MDR-TB in 2006, and 72.4 percent of these were in Asia. Together, China and India accounted for half of all the cases.

South Africa has 6,000 new MDR-TB cases each year.

"We (Asia) have the greatest number because the most populous countries with MDR-TB are in Asia," Thelma Tupasi, president of the Tropical Disease Foundation in the Philippines, told the conference.

Tupasi urged health authorities to implement programs requiring TB patients to take drugs while being observed by trained healthcare workers, or what is known as Directly Observed Therapy.

Standard TB takes between 6 to 12 months to treat, and drug-resistant forms of TB take even longer than that, and patients often cannot stick to the regimens without proper supervision.

"You have to give it to them and you must see with your own eyes that they take it. If you leave it to the patients, there will be a lot of non-adherence, and that creates MDR-TB," Tupasi told Reuters later.

REUTERS

http://www.reuters.com/

http://www.reuters.com/article/healthNews/idUSB70242420080622?sp=true

Share this page
Email this page to a friend Share this page on Digg Share this page on StumbleUpon Share this page on del.icio.us Share this page on Reddit Share this page on Facebook More...

DISCLAIMER

The EATG is not responsible for the content of this article. It does not necessarily reflect EATG views or opinions.

FAIR USE NOTICE

The information above may contain copyrighted material which has not always been specifically authorised by the copyright owner. Such material is made available for educational purposes to advance the understanding of scientific, ethical, legal and social issues. It is believed that this constitutes a 'fair use' of any such copyrighted material. This material is distributed without profit via the subscription to the daily digest.
European AIDS Treatmen.../Global HIV News/News archive/
Print